drugset / Trial / NCT05957913

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

NCT05957913

Phase 2 Enrolling by invitation 50 enrolled Massachusetts General Hospital Solving MS · collab
NaSingle-groupOpen-labelBasic science

Summary

This research study is being performed to find out if Truvada (tenofovir/emtricitabine), an antiviral drug with activity against the Epstein Barr virus (EBV), can reduce EBV levels in saliva and blood in people with multiple sclerosis (MS). A second goal is to find out if Truvada (tenofovir/ emtricitabine) is safe and tolerable in people with MS.

Timeline

Start
2023-06-05
Primary completion
2027-06-04
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 300 mg
Subject emtricitabine Other / unclassified 200 mg

Indications